




STAT3 and TP53 mutations associate with poor prognosis
in anaplastic large cell lymphoma
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To the Editor:
Systemic anaplastic large cell lymphoma (sALCL) encom-
passes two distinct clinical entities of T-cell non-Hodgkin
lymphoma: anaplastic lymphoma kinase-positive (ALK+)
ALCL and ALK-negative (ALK−) ALCL. These entities
are characterized by either the presence or absence of an
ALK translocation. It has been reported that ALK+ ALCL
has a better prognosis compared to ALK−, with a 5-year
overall survival (OS) of 70–80% versus 40–60%, respec-
tively, [1–3]. Furthermore, more than 30% of ALK+ ALCL
patients relapse [4, 5]. Despite the distinction between the
two sALCL subtypes, frontline treatment for adults is
similar and is based on CHOP or CHOEP, instead pediatric
ALCL patients are mainly treated following the ALCL99
protocol [6–8]. Whilst high-throughput genomic studies in
sALCL have shown recurrent genetic alterations, their
association with outcome has not been fully investigated
[9–13].
In this study, the mutational landscape of sALCL patient
tumors was investigated to discover potential biomarkers
that may improve risk stratification and patient
management.
A cohort of 82 sALCL patient tumors (47 ALK+ and 35
ALK−) and 6 ALCL cell lines (4 ALK+, 2 ALK−)
(Table S1) were subjected to deep targeted next-generation
sequencing analyzing the whole coding regions of 275
cancer related genes (Table S2). The average depth
achieved across all the samples sequenced was ~2000×.
Sequencing data are available at Sequence Read Archive
(https://www.ncbi.nlm.nih.gov/sra/, SRA identifier
PRJNA602225).
Male subjects were predominant in both subgroups
of our cohort, 57.4% in ALK+ versus 67.6% in ALK−.
ALK+ patients were significantly younger than ALK−
patients with an average age of 22.7 (3–61) and 55.2
(27–81) years, respectively. ALK+ ALCL patients had a
longer survival than ALK− ALCL with a 7-year OS of
77.6% and 46.7%, respectively, and with 7-year progression
free survival (PFS) being comparable at 58.7% for ALK+
and 44.1% for ALK− patients (Fig. S1). The first line of
treatment for all the adult patients was systemic che-
motherapy, and most of the childhood ALK+ ALCL
patients (80%) were treated following the ALCL99 or
ALCL98 protocols. Although ALK+ patients have a longer
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OS, more than 30% relapsed after first-line treatment.
Among the 275 genes analyzed, we identified 148 (54%)
genes harboring at least one mutation throughout the entire
cohort; 132 genes among the patients and 43 among the cell
lines, with 27 genes in common (Fig. S2, Table S3).
Overall, 72 out of 82 (88%) patients carried at least one
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mutation within the genes analyzed. We detected an average
of 4.2 mutations per patient in ALK− ALCL and an aver-
age of 2.7 in ALK+ ALCL. The most recurrently mutated
gene in the entire cohort was TP53 found in 16% of sALCL
patients (11% ALK+, 23% ALK− and in all ALK+ cell
lines). Interestingly, for the ALK+ group, mutated TP53
was more frequent in young patients (p < 0.04). LRP1B was
prevalently mutated in ALK+ patients (19%) and in three
cell lines. STAT3 and JAK1 were mutated solely in ALK−
ALCL, both with a prevalence of 26%, and were the most
mutated genes in this group (Fig. 1a). Recurrent mutations
were detected in epigenetic modifier genes also recently
reported to be frequently mutated in BIA-ALCL [14].
KMT2D and TET2 were found mutated in ALCL patients
regardless of ALK status and EP300 and KMT2C only in
ALK+ patients. Pathway enrichment analysis showed a
significant enrichment in mutated genes involved in JAK/
STAT (p < 0.003) and PI3K/AKT signaling pathways (p <
0.02) for ALK− ALCL compared with ALK+ ALCL
(Fig. 1b). We investigated possible correlations between the
existence of mutations in the most mutated genes and the
clinical characteristics of our cohort. Poor prognostic out-
come was defined as patients meeting at least one of the
following criteria: deceased, unresponsive to treatment and/
or disease relapse. The most recurrently mutated genes in
the poor prognostic sub-cohort independent of ALK status
were TP53 (27%), STAT3 (24%), EPHA5 (16%), JAK1
(16%), PRDM1 (13.5%), LRP1B (11%) and KMT2D (11%).
Considering only refractory/relapsed ALCL patients,
mutations within TP53 (28%) and EPHA5 (19%) were the
most common (Table S4). In relation to the prognosis, ALK
+ patients did not show any significant difference in the
signaling pathways affected by mutations. On the contrary,
the JAK/STAT (p < 0.005) and PI3K/AKT pathways (p <
0.036) were enriched in ALK− ALCL patients with an
inferior outcome (Fig. 1b). Pathogenetic variants of STAT3
were detected in 9/35 (26%) of ALK− ALCL patients.
Mutations were located mainly within the SH2 domain
(S614R, E616G, Y640F, N647I, K658delinsNM and
D661V) and in one case within the DNA binding domain
(C426R). Mutated JAK1 was detected in 9/35 (26%) of
ALK− ALCL patients and of those, 6/9 were at the hotspot
codon 1097 (G1097D/F/N/S) (Fig. 1d). For four patients,
JAK1 was mutated together with STAT3, thereby empha-
sizing the importance of the JAK/STAT signaling axis. To
evaluate the prognostic value of mutations in the JAK/
STAT pathway, we performed Cox regression analysis and
showed that ALK− ALCL patients harboring STAT3 and/or
JAK1 mutation have a shorter OS (hazard ratio [HR]= 2.8;
95% confidence interval [CI], 1.1–7.1, p < 0.03) (Fig. S3A).
Furthermore, the prognostic value of the most mutated
genes in ALK− ALCL: STAT3 (9/35), JAK1 (9/35), TP53
(8/35) and KMT2D (7/35) were investigated. Cox regression
analysis showed that patients with STAT3 mutations have a
significantly shorter OS compared to those with wild-type
STAT3 (HR= 4.1; 95% CI, 1.56–10.71, p < 0.002)
(Fig. 1c). In addition, while JAK1 and KMT2D mutations
did not significantly correlate with OS (p < 0.2 and p < 0.3,
respectively), TP53 mutations clearly displayed the corre-
lation (p < 0.01) (Fig. S3B–D). To further confirm that
mutations in STAT3 are associated with shorter OS, we
applied Akaike’s informative criteria model to the four
aforementioned genes. STAT3 mutations were found to be
the best predictor of OS in ALK− ALCL (Table S5).
Moreover, no significant differences were found between
mutation status of these genes with age, gender, disease
stage, eastern cooperative oncology group performance
status or age-adjusted international prognostic index (AA-
IPI). As expected [9, 13, 15], expression of p-STAT3
(Y705) was detected at a high level in all ALK− ALCL
patients harboring STAT3 mutations, although low/medium
expression of p-STAT3 was also detected in STAT3 wild-
type patient tumors (Fig. S4, Table S6). Mutations in the
LRP1B gene were detected in 12/82 (15%) of sALCL
patients (19% ALK+ and 9% ALK−) and three cell lines.
Since LRP1B was the most recurrently altered gene in ALK
+ ALCL, we assessed its possible association with out-
come, but no differences were found between mutated and
nonmutated patients.
To investigate somatic mutations with a possible role in
disease relapse, we sequenced paired diagnostic and relapse
samples available for four patients (1 ALK+ and 3 ALK−)
(Fig. 2a). Two different acquired mutations in EPHA5 were
detected in each of the two relapse samples (patient tumors
Fig. 1 Mutational landscape in sALCL reveals prognostic biomarkers.
a Oncoplot shows the genes mutated in at least 5% of the entire cohort.
The percentage is shown on the left axis. Each column represents a
patient, ALK+ in dark green and ALK− ALCL patients in dark
orange. The black bars on the top represent the number of mutated
genes in each patient. On the right axis, the frequency of mutated gene
in ALK+ (dark green) and ALK− (dark orange) ALCL patients. The
green bar on the bottom shows the age of each patient. Mutation types
are represented in different colors as shown in the legend. b Percentage
of patients harboring at least one mutated gene in ten biological
pathways. The yellow colored portion next to each pathway indicates
the percentage of genes present in our panel that belong to that specific
pathway according to the KEGG database. For each pathway shown,
the patients are divided according to prognosis; red: patients with poor
prognosis; green: patients with good prognosis; gray: patients for
whom clinical information is not available (NA); light blue patients
wildtype (WT) that do not harbor mutated genes in that specific
pathway. The patients are represented as percentage of the total. DDR
and repair DNA damage response and repair pathway, TFs transcrip-
tion factors. Fisher’s exact test: *p < 0.05, **p < 0.01 and ***p <
0.001. c 7-year OS of ALK− ALCL patients according to STAT3
status: STAT3 mutated (red) versus STAT3 wt (blue). P values and
hazard ratios (HR) shown were determined by the Cox proportional
hazards model. d Schematic representation of STAT3 and JAK1
domains and the position of the variants.
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
ALK+ 1R and HK-10R): a stop codon at S566 and a
glycine–valine change at residue 723. In the latter patient
(HK-10), identification of mutated EPHA5 appears to be the
result of the emergence of a new malignant clone, harboring
novel mutations in several other genes consistently with a
similar variant allele frequency (Fig. 2b). Interestingly,
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EPHA5 was also found to be the second most mutated gene
in relapsed/refractory patients in the entire cohort
(Table S4B). Three out of four patients harbored mutated
TP53 both at diagnosis and at relapse (Fig. 2b). As TP53 is
the most recurrent gene mutated in our cohort and the most
mutated gene in relapsed patients (Table S4B), we investi-
gated its possible association with the treatment outcome for
all ALCL patients regardless of ALK status. Nearly all
mutations in TP53 were detected in the DNA binding
domain except for L344P in the TET domain for one patient
(Fig. 2d). sALCL patients harboring TP53 mutations have a
shorter PFS compared to those with the wild-type gene
(HR= 3.3; 95% CI, 1.59–6.87, p < 0.0007) (Fig. 2c). These
data, together with the diagnosis versus relapse analysis,
suggest that TP53 mutations may confer resistance to che-
motherapy. Moreover, mutations in TP53 were the most
common genetic events on re-analysis of publicly available
datasets (Table S7) [9, 11].
Losses at the genomic regions that encompass TP53 and
PRDM1 genes have been shown to be the most common
lesions in sALCL with a clinical implication [12]. PRDM1
mutations were detected in five patients, with three of these
co-occurring with TP53 mutations and all five patients
being categorized within the poor prognostic sub-group.
These data confirm the correlation between TP53 and
PRDM1 gene mutations, thereby demonstrating either copy
number loss or concomitant mutations are mechanisms
which have the potential to alter p53 and PRDM1 pathways
activity.
In summary, within one of the largest cohort of
82 sALCL patients, we provide robust information on the
genetic spectrum of genes either solely mutated in ALK−
ALCL (STAT3, JAK1) or across the whole spectrum of
ALCL (TP53, LRP1B, EPHA5, KMT2D). In addition, we
describe novel biomarkers for predicting treatment outcome
reporting an association between mutated STAT3 and TP53
with an inferior outcome, in the former case in ALK−
disease and in the latter case all sALCL independent of
ALK status. Finally, this mutational landscape provides
further candidate genes that deserve consideration for their
possible role in the patient outcome, such as EPHA5,
KMT2D, PRDM1 and SOCS1.
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